FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
489PDF: 2 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
566PDF: 6 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
440PDF: 90 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
518PDF: 3 -
Anticoagulation in obese patients: challenges and strategies
1975PDF: 479HTML: 290XML: 172 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2810PDF: 472Supplementary Files: 131 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
579PDF: 2 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
529PDF: 6 -
The key to fibrinolysis and thrombolysis
1631PDF: 498HTML: 240 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
820PDF: 102HTML: 107Supplementary: 64Appendix: 70 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1272PDF: 192HTML: 117Appendix: 108 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
597PDF: 2 -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
621PDF: 1 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
748PDF: 2 -
PO32 | Effect of the sodium-glucose co-transporter-2 (SGLT2) inhibitors on platelet activation and lipid peroxidation: results of a pilot study P.G.M. Simeone1, R. Liani1, M. Alfonsetti1, B. Cancelli1, M. Frezza1, G. Raggiunti1, S. Zeeba2, F. Cipollone1, G. Renda2, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, University of Chieti; 2Department of Neuroscience, Imaging and Clinical Sciences, G. D’Annunzio University of Chieti-Pescara; 3University Cardiology Division, Heart Department, Policlinico SS Annunziata, Chieti, Italy
561PDF: 1 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
588PDF: 1 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
583PDF: 5 -
PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti1, F. Schieppati1, C. Ambaglio1, M. Marchetti1, L. Barcella1, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy
325PDF: 74 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
560PDF: 2 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
612PDF: 6 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
585PDF: 2 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
365PDF: 96 -
CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia V. Castellani1, V. Cammisotto2, F. Baratta2, S. Bartimoccia3, C. Nocella2, L. D’erasmo1, N. Cocomello2, C. Barale4, R. Scicali5, I. Russo4, F. Purrello5, R. Carnevale3, F. Violi2, M. Arca1, P. Pignatelli2 | 1Department of Translational and Precision Medicine, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Roma; 3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma; 4Department of Clinical and Biological Sciences, University of Turin; 5Department of Clinical and Experimental Medicine, Internal Medicine, University of Catania, Italy
577PDF: 3 -
PO53 | Effectiveness and safety of DOACS in patients with renal transplantation A. Ierardi, A. Strangio, M. Leotta, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU Renato Dulbecco, Catanzaro, Italy
605PDF: 2 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
383PDF: 97 -
PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK
421PDF: 100 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
617PDF: 5 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
354PDF: 91 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
575PDF: 6 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
711PDF: 5 -
PO69 | Whole blood thrombin generation hypercoagulable profile in a patient with hemolytic crisis due to paroxysmal nocturnal hemoglobinuria: a case report A. Napolitano, L. Spiezia, C. Bulato, E. Campello, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
653PDF: 1 -
PO46 | Intravitreal treatment with faricimab in patients with age-related macular degeneration M. Alfonsetti1, R. Liani1, P.G.M. Simeone1, M. Frezza1, A. Ricci3, S. Lattanzio1, R. D’Aloisio2, L. Toto2, F. Santilli1 | 1Department of Medicine and Aging, Center for Advanced Studies and Technology “CAST”; 2Ophthalmology Clinic, Department of Medicine and Aging; 3Department of Pharmacy, University “G. d’Annunzio” of Chieti Pescara, Chieti, Italy
438PDF: 2 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
594PDF: 2 -
PO68 | Whole blood hypercoagulable profiles in a patient with markedly elevated lipoprotein(A) plasma levels and thrombotic complications: a case report C. Portinari, M. Biolo, A. Napolitano, L. Spiezia, A. Colpo, S. Zambon, A. Zambon, P. Simioni | Department of Medicine, Padova University Hospital, Padova, Italy
606PDF: 6 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
416PDF: 84 -
CO27 | Intracerebral hemorrhage in hemophilia A and B: a 10-year prospective multicenter study in Italy (2012–2022) E. Zanon1, A. Napolitano1, A. Porreca2, F. Demartis3, A. Coppola4, C. Santoro5, I. Cantori6, A. C. Molinari7, C. Biasioli8, M. Luciani9, G. Sottilotta10, B. Pollio11, A. Borchiellini12, A. Tosetto13, P. Flora14, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Department of Human Sciences and Promotion of the Quality of Life, Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele Roma Open University, Roma; Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele, Roma; 3Centre for Bleeding Disorders, Careggi University Hospital of Firenze; 4Azienda Ospedaliero Universitaria di Parma; 5Hematology Division, Umberto I University Hospital of Roma; 6Haemophilia Center, Department of Transfusion Medicine, Hospital of Macerata; 7IRCCS Istituto Giannina Gaslini, Genova; 8Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena; 9Children’s Hospital Bambino Gesù, Roma; 10Haemophilia Center, Department of Onco-Hematology and Radioterapy, Hospital of Reggio Calabria; 11Haemophilia Pediatric Center, Transfusion Medicine, City of Health and Science of Turin; 12City of Health and Science of Turin; 13Hemorrhagic and Thrombotic Diseases Unit, S. Bortolo Hospital of Vicenza; 14RCCS Foundation Ca’ Granda Maggiore Policlinico Hospital, Milan, Italy
629PDF: 6 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
519PDF: 2
1 - 46 of 46 items
